Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCOLN3 | Q8TDD5 | 3/20 | 0.72 |
| ▸ | TSHR | P16473 | 7/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.68 |
| ▸ | GAA | P10253 | 2/20 | 0.68 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10568810 | 0.87 | MAPT (0.62) | MCOLN3TSHRALDH1A1GAANPBWR1 | |
| SCHEMBL10156486 | 0.86 | ALDH1A1 (0.63) | MCOLN3TSHRALDH1A1GAANPBWR1 | |
| SCHEMBL10126519 | 0.80 | SMN1; SMN2 (0.64) | MCOLN3TSHRALDH1A1GAAKDM4E | |
| SCHEMBL10157657 | 0.80 | MCOLN3 (0.68) | MCOLN3TSHRALDH1A1GAANPBWR1 | |
| SCHEMBL25920388 | 0.78 | TSHR (0.57) | TSHRALDH1A1NPBWR1KDM4ELMNA | |
| SCHEMBL30270512 | 0.78 | TSHR (0.57) | TSHRALDH1A1NPBWR1KDM4ELMNA | |
| SCHEMBL2767267 | 0.78 | SMN1; SMN2 (0.61) | MCOLN3TSHRALDH1A1GAAKDM4E | |
| SCHEMBL281571 | 0.78 | MCOLN3 (0.65) | MCOLN3TSHRALDH1A1GAANPBWR1 | |
| SCHEMBL23326420 | 0.77 | ALDH1A1 (0.67) | TSHRALDH1A1LMNAKMT2APOLB | |
| SCHEMBL29451365 | 0.77 | ALDH1A1 (0.67) | TSHRALDH1A1LMNAKMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9487491-B2 | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC. (JP) | 2016-11-08 | — | — | US | disclosed |
| US-8969336-B2 | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC. (JP) | 2015-03-03 | — | — | US | disclosed |
| US-20140371196-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-12-18 | — | — | US | disclosed |
| US-20120040968-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | WATERS TECHNOLOGIES CORPORATION (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371196-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | EML4, ALK, ERBB4 | MCOLN3 2528/4885TSHR 3964/4885ALDH1A1 1554/4885 |
| US-20120040968-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | EML4, ALK, ERBB4 | MCOLN3 2528/4885TSHR 3964/4885ALDH1A1 1554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.